|1.||Centers for Disease Control and Prevention (CDC): 75 articles (06/2015 - 05/2000)|
|2.||Esposito, Susanna: 30 articles (01/2016 - 07/2002)|
|3.||Principi, Nicola: 27 articles (01/2016 - 07/2002)|
|4.||Ambrose, Christopher S: 26 articles (09/2014 - 10/2006)|
|5.||Cox, Nancy J: 25 articles (11/2015 - 04/2002)|
|6.||Shay, David K: 25 articles (06/2015 - 12/2005)|
|7.||Jackson, Lisa A: 21 articles (09/2015 - 10/2002)|
|8.||Edwards, Kathryn M: 21 articles (09/2015 - 01/2004)|
|9.||De Serres, Gaston: 20 articles (09/2015 - 06/2002)|
|10.||Nowalk, Mary Patricia: 20 articles (07/2015 - 05/2003)|
|1.||Human Influenza (Influenza)
12/29/2001 - "Studies in children and adults revealed cold-adapted, live, attenuated, trivalent, intranasal influenza vaccine (CAIV-T) to be well accepted, well tolerated and highly protective against culture-confirmed influenza, and to provide significant health benefits. "
01/01/2014 - "Comparative evaluation of live attenuated and inactivated influenza vaccines based on data from direct comparative studies is necessary for ensuring the most effective and safe vaccination against influenza. "
07/01/2013 - "In most seasons, the influenza vaccine is effective in preventing influenza, but it is not clear whether it is equally effective in preventing mild and severe cases. "
01/01/2013 - "Current influenza vaccines are moderately effective, with current evidence suggesting that they can prevent about half of influenza-associated symptomatic illness, outpatient visits, hospitalizations and deaths, with the evidence weaker for the most serious complications. "
07/01/2011 - "The most profound consequences of immune senescence with respect to public health are the increased susceptibility to influenza and loss of efficacy of the current split-virus influenza vaccines in older adults, which are otherwise very effective in younger populations. "
08/01/2015 - "Overall, our data show that the repeated low-dose influenza A virus infection mouse model is more stringent and may thus be more suitable to select for highly efficacious influenza vaccines. "
01/01/2012 - "Remarkably, GPI-0100-adjuvanted influenza vaccine given at a low dose of 2×1 µg either in the nares or directly into the lungs provided complete protection against homologous influenza virus infection."
01/01/2008 - "Further delineation of the roles of NK cells and innate immunity in viral infection may have important implications for the development of improved influenza virus vaccines. "
07/01/2011 - "Despite some limitations, this study indicates that the first seasonal trivalent influenza vaccine to include the pandemic (H1N1) 2009 virus strain provided significant protection against laboratory-confirmed pandemic (H1N1) 2009 infection."
01/01/2014 - "In 3035 adults aged 14-64 years, administration of the influenza vaccine significantly reduced the frequency of infection (P<0.01) in the 2008 and 2010 seasons, but not in the 2009 and 2011 seasons. "
12/01/1998 - "Despite the proven efficacy of the influenza vaccine in reducing the risk for pneumonia, hospitalization, and death and the potential savings in costs, most elderly persons do not receive annual immunizations. "
05/01/2005 - "23-valent pneumococcal vaccine (PV) seems to be clinically effective in preventing pneumonia in HIV-infected patients, and even more if strengthened by influenza vaccine."
07/01/2013 - "Inactivated influenza vaccines for prevention of community-acquired pneumonia: the limits of using nonspecific outcomes in vaccine effectiveness studies."
03/01/2010 - "Influenza vaccine trials against childhood pneumonia are warranted."
01/29/2009 - "As part of an integrated four-stage strategy, both pneumococcal and influenza vaccine impact on pneumonia burden reduction should be evaluated in controlled trials in tropical and sub-tropical Asian and African countries, along with evaluation of new aetiology diagnostics, research into common pneumonia mortality pathways and interventions targeting those pathways."
|4.||Influenza in Birds (Avian Flu)
04/01/2009 - "Efficacy of a commercial inactivated H5 influenza vaccine against highly pathogenic avian influenza H5N1 in waterfowl evaluated under field conditions."
01/01/2009 - "This, along with the ominous threat of an avian influenza pandemic (H5N1), demonstrates the need for a much improved, more sophisticated influenza vaccine. "
07/01/2014 - "We used African green monkeys (AGMs) as a nonhuman primate (NHP) model for a comprehensive and comparative evaluation of pairs of wild-type and pandemic live attenuated influenza virus vaccines (pLAIV) representing four subtypes of avian influenza viruses and found that pLAIVs replicate similarly in AGMs and humans and that AGMs can be useful for evaluation of the protective efficacy of pLAIV."
11/12/2014 - "In this study, we evaluated a potential live influenza vaccine candidate using an H7N3 avian influenza virus isolated from ducks with controls of two recombinant viruses generated through reverse genetics. "
01/01/2014 - "Assessment of human immune responses to H7 avian influenza virus of pandemic potential: results from a placebo-controlled, randomized double-blind phase I study of live attenuated H7N3 influenza vaccine."
06/01/2007 - "The influenza vaccine is cost-effective for working-age cancer patients with a life expectancy of >or=3 months. "
06/01/2010 - "The aim of this study was to investigate the efficacy of the influenza vaccine among cancer patients in Taiwan. "
09/15/2013 - "Both the B16lacZ and 4T1 tumor models in immunocompetent mice were used to assess the in vivo efficacy of perioperative influenza vaccine administration. "
09/15/2013 - "In human studies, influenza vaccine significantly enhanced NK cell activity in healthy human donors and cancer surgery patients. "
01/01/2013 - "Randomized controlled trials (RCTs), prospective and retrospective cohort studies and case-control studies were considered, comparing inactivated influenza vaccines versus placebo, no vaccination or a different vaccine, in adults (16 years and over) with cancer. "
|4.||Antiviral Agents (Antivirals)
|5.||Influenza Vaccines (FluMist)
|9.||Immunoglobulin A (IgA)
|2.||Day Care (Partial Hospitalization)
|3.||Home Nursing (Nursing, Home)
|4.||Drug Therapy (Chemotherapy)